Table 1.
Characteristics of patients between 18 to 70 years of age who underwent allogeneic transplant for AML between 1995 and 2010 reported to the CIBMTR
| Characteristics of patients | No-extramedullary disease | Extramedullary | P-value |
|---|---|---|---|
| Number of patients | 8983 | 814 | |
| Number of centers | 299 | 178 | |
| Age, median (range) | 46 (18–70) | 42 (18–70) | <0.001 |
| Age in decades | <0.001 | ||
| 18–29 | 1533 (17) | 199 (24) | |
| 30–39 | 1599 (18) | 164 (20) | |
| 40–49 | 2311 (26) | 206 (25) | |
| 50–59 | 2364 (26) | 186 (23) | |
| 60–70 | 1176 (13) | 59 (7) | |
| Sex | 0.03 | ||
| Male | 4692 (52) | 458 (56) | |
| Female | 4291 (48) | 356 (44) | |
| Karnofsky score | 0.01 | ||
| <90% | 2877 (32) | 301 (37) | |
| >=90% | 5652 (63) | 470 (58) | |
| Missing | 454 (5) | 43 (5) | |
| Sub-disease | <0.001 | ||
| M0-M1 | 1737 (19) | 124 (15) | |
| M2 Myelocytic | 2014 (22) | 91 (11) | |
| M4-M5 | 2579 (29) | 374 (46) | |
| M6 Erythroblastic | 311 (3) | 7 (<1) | |
| M7 Megakaryoblastic | 137 (2) | 12 (1) | |
| Granulocytic sarcoma with unknown subtype | 0 | 71 (8) | |
| AML with t(8;21)(q22;q22)(AML1/ETO) | 39 (<1) | 8 (<1) | |
| AML with abnormal BM eosinophils (CBFb/MYH11) | 37 (<1) | 4 (<1) | |
| AML with multi-lineage dysplasia | 530 (6) | 21 (3) | |
| AML, other specified | 250 (3) | 36 (4) | |
| AML, subtype unknown | 1349 (16) | 66 (8) | |
| White blood count at diagnosis, ×10^9/L | <0.001 | ||
| Median (range) | 9 (<1–1000) | 22 (<1–600) | |
| <= 10 | 3998 (45) | 253 (31) | |
| 10 – 100 | 2965 (33) | 334 (41) | |
| > 100 | 707 (8) | 120 (15) | |
| Missing | 1313 (15) | 107 (13) | |
| Cytogenetic abnormalities | <0.001 | ||
| Favorable | 555 (6) | 72 (9) | |
| Intermediate | 4129 (46) | 407 (50) | |
| Poor | 1752 (20) | 140 (17) | |
| Missing | 2547 (28) | 195 (23) | |
| Previous history of MDS | <0.001 | ||
| No | 7182 (80) | 709 (87) | |
| Yes | 1709 (19) | 94 (12) | |
| Missing | 92 (1) | 11 (1) | |
| Disease status prior to conditioning | <0.001 | ||
| Primary induction failure | 1313 (15) | 97 (12) | |
| CR1 | 4367 (49) | 305 (37) | |
| >=CR2 | 1773 (20) | 214 (26) | |
| Relapse | 1530 (17) | 198 (24) | |
| Extramedullary disease | N/A | ||
| Not present | 8983 | 0 | |
| At both diagnosis and transplant | 0 | 60 (7) | |
| At diagnosis only | 0 | 542 (67) | |
| At transplant only | 0 | 159 (20) | |
| CNS leukemia present any time prior to conditioning | 0 | 53 (7) | |
| Site of extramedullary diseasea | |||
| Any CNS | 0 | 283 (35) | |
| Skin only | 0 | 155 (19) | |
| Lymph node only | 0 | 112 (14) | |
| Other | 0 | 264 (32) | |
| Not applicable | 8983 | 0 | |
| Time from extramedullary disease to transplant, months | N/A | 5 (<1–133) | |
| Time from diagnosis to transplant, months | 0.21 | ||
| Median (range) | 6 (<1–321) | 7 (<1–200) | 0.23 |
| <6 | 4188 (47) | 360 (44) | |
| 6 – 12 | 2451 (27) | 231 (28) | |
| >12 | 2338 (26) | 221 (27) | |
| Missing | 6 (<1) | 2 (<1) | |
| Conditioning regimen combination | <0.001 | ||
| MA with TBI | 3123 (35) | 383 (47) | |
| MA without TBI | 3562 (40) | 283 (35) | |
| RIC/NMA | 2298 (26) | 148 (18) | |
| Type of donor | <0.001 | ||
| HLA-identical sibling | 3536 (39) | 360 (44) | |
| Well-matched unrelated | 3057 (34) | 243 (30) | |
| Partially-matched unrelated | 1547 (17) | 119 (15) | |
| Mismatched unrelated | 487 (5) | 40 (5) | |
| Unrelated unknown | 356 (4) | 52 (6) | |
| Graft type | 0.97 | ||
| Bone marrow | 3229 (36) | 292 (36) | |
| Peripheral blood | 5754 (64) | 522 (64) | |
| Year of transplant | 0.01 | ||
| 1995–2000 | 2446 (27) | 259 (32) | |
| 2001–2005 | 3213 (36) | 262 (32) | |
| 2006–2010 | 3324 (37) | 293 (36) | |
| Median follow-up of survivors (range), months | 60 (3–194) | 58 (3–191) | |
| Patients transplanted in CR2 only | 1649 | 200 | |
| Duration of CR1, months | <0.001 | ||
| Median (range) | 11 (<1–187) | 9 (<1–110) | <0.001 |
| <6 | 308 (19) | 63 (32) | |
| 6 – 12 | 475 (29) | 59 (30) | |
| >12 | 631 (38) | 53 (27) | |
| Missing | 235 (14) | 25 (13) |
a
Other sites of extramedullary disease include:
liver/spleen only, n=45; multiple sites, n=69; other specified, n=150
example of other specified: pelvic soft tissue mass; salivary gland chloroma; mass in right lung base; gum pyperplacy ecxema (paws); breast infiltrate; left mandible; gastric chloroma; bone (knee); thorencentesis fluid; polychondritis etc.